- Home
- PL vs AKBA Comparison
PL vs AKBA Comparison
Compare PL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PL
- AKBA
- Stock Information
- Founded
- PL 2010
- AKBA 2007
- Country
- PL United States
- AKBA United States
- Employees
- PL N/A
- AKBA 181
- Industry
- PL Aerospace
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- PL Industrials
- AKBA Health Care
- Exchange
- PL Nasdaq
- AKBA Nasdaq
- Market Cap
- PL 947.7M
- AKBA 861.7M
- IPO Year
- PL N/A
- AKBA 2014
- Fundamental
- Price
- PL $6.78
- AKBA $3.25
- Analyst Decision
- PL Buy
- AKBA Strong Buy
- Analyst Count
- PL 13
- AKBA 5
- Target Price
- PL $6.12
- AKBA $6.90
- AVG Volume (30 Days)
- PL 5.9M
- AKBA 4.0M
- Earning Date
- PL 09-08-2025
- AKBA 08-07-2025
- Dividend Yield
- PL N/A
- AKBA N/A
- EPS Growth
- PL N/A
- AKBA N/A
- EPS
- PL N/A
- AKBA N/A
- Revenue
- PL $250,177,000.00
- AKBA $203,733,000.00
- Revenue This Year
- PL $15.09
- AKBA $27.95
- Revenue Next Year
- PL $20.58
- AKBA $43.88
- P/E Ratio
- PL N/A
- AKBA N/A
- Revenue Growth
- PL 9.52
- AKBA 16.75
- 52 Week Low
- PL $1.76
- AKBA $1.24
- 52 Week High
- PL $7.72
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- PL 60.21
- AKBA 40.09
- Support Level
- PL $6.16
- AKBA $2.92
- Resistance Level
- PL $6.98
- AKBA $3.44
- Average True Range (ATR)
- PL 0.35
- AKBA 0.17
- MACD
- PL 0.01
- AKBA -0.05
- Stochastic Oscillator
- PL 81.98
- AKBA 37.08
About PL Planet Labs PBC
Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.